Clinical utility of varenicline for smokers with medical and psychiatric comorbidity / Jon O. Ebbert (2009)

Public Titre : Clinical utility of varenicline for smokers with medical and psychiatric comorbidity Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Kirk D Wyatt, Auteur ; Michael V. Burke, Auteur ; J. Taylor Hays, Auteur ; Ali Zirakzadeh, Auteur Editeur : Dove Medical Press Année de publication : 2009 Collection : International journal of Chronic Obstructive Pulmonary Disease, ISSN 1178-2005 num. 4 Importance : p. 421-430 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline [TABAC] tabagisme:pathologie:pathologie respiratoire:broncho-pneumopathie chronique obstructive Index. décimale : TA 6.2.3.2 Autres produits Résumé : Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8134

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Combination treatment with varenicline and nicotine replacement therapy / Jon O. Ebbert (2009)

Public Titre : Combination treatment with varenicline and nicotine replacement therapy Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Michael V. Burke, Auteur ; Richard D. Hurt, Auteur Editeur : Oxford University Press Année de publication : 2009 Collection : Nicotine and Tobacco Research num. Vol 11, n. 5 Importance : p. 572-576 Langues : Anglais (eng) Catégories : [TABAC] étude [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract INTRODUCTION: A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT). METHODS: We reviewed the clinical experience of two groups of cigarette smokers enrolled in a residential tobacco treatment program: (a) patients receiving combination treatment with varenicline and NRT (N = 104) and (b) usual-care patients receiving treatment before the release of varenicline (N = 135). RESULTS: Demographic characteristics were similar between the two groups. Among smokers receiving varenicline and NRT, 71% used the nicotine patch with a mean dose of 32 mg/day (SD = 14) and 73% used at least two types of NRT. Adverse events were experienced by 39% (95% CI = 31%-49%) of patients receiving varenicline and NRT and by 59% (95% CI = 51%-67%) of usual-care patients during the residential program. A total of five patients (5%) discontinued varenicline due to adverse events, compared with one patient in the usual-care group. We did not observe a significant difference in the 30-day point prevalence smoking abstinence rate at 6 months between patients treated with varenicline and NRT (54%; 95% CI = 44%-64%) and usual-care patients (59%; 95% CI = 50%-66%). DISCUSSION: Our findings suggest that combination therapy with varenicline and NRT is safe and well tolerated among patients in a residential tobacco treatment program. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7950

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005491	TA 6.2.3.1.4 EBB C	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !